A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 13 Jan 2014
At a glance
- Drugs Sorafenib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PECASO
- 31 Aug 2018 Biomarkers information updated
- 27 Dec 2012 Additional lead trial centre added as reported by German Clinical Trials Register.
- 01 Aug 2012 New source identified and integrated (DRKS00003807: German Clinical Trials Register).